Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety and Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Path (2022–2024)
- Grant type:
- Janssen-Cilag Pty Limited (Janssen-Cilag Australia)
- Researchers:
-
-
- Funded by:
- Janssen-Cilag Pty Limited (Janssen-Cilag Australia)
